Fulton Bank N.A. Sells 9,171 Shares of Gilead Sciences, Inc. $GILD

Fulton Bank N.A. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 12,725 shares of the biopharmaceutical company’s stock after selling 9,171 shares during the period. Fulton Bank N.A.’s holdings in Gilead Sciences were worth $1,773,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Norges Bank bought a new stake in shares of Gilead Sciences during the fourth quarter worth $2,617,152,000. Boston Partners bought a new stake in Gilead Sciences in the 4th quarter valued at $517,808,000. Massachusetts Financial Services Co. MA boosted its stake in Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares during the period. Bank of America Corp DE increased its holdings in Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $131.27 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The business’s 50-day simple moving average is $129.48 and its 200 day simple moving average is $134.56. The firm has a market capitalization of $162.98 billion, a PE ratio of 17.88 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GILD. Jefferies Financial Group initiated coverage on Gilead Sciences in a report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research report on Tuesday, June 16th. Citigroup boosted their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Truist Financial reaffirmed a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a research note on Monday, June 8th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $158.41.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,000 shares of company stock worth $10,824,500 over the last quarter. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.